Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Systemic infection11.01.08.0500.000139%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.002085%
Myeloproliferative neoplasm01.13.03.006; 16.21.03.0060.000139%Not Available
Liver function test increased13.03.01.044--Not Available
Acute myelomonocytic leukaemia01.10.05.005; 16.01.05.0050.000139%Not Available
Breast cancer recurrent21.05.01.017; 16.10.01.0090.000799%Not Available
Cerebellar haemorrhage24.07.04.023; 17.08.01.0460.000139%Not Available
Chloroma16.01.08.003; 01.10.08.0030.002664%Not Available
Concomitant disease aggravated08.01.03.0630.000278%Not Available
Diverticulitis intestinal haemorrhagic24.07.02.033; 11.01.07.021; 07.10.02.0020.000139%Not Available
Full blood count decreased13.01.07.0040.006127%Not Available
Haemorrhoids thrombosed24.10.02.006; 07.15.03.0050.000533%Not Available
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.000208%Not Available
Lymph node tuberculosis11.04.01.002; 01.09.01.0040.000533%Not Available
Pancreatic carcinoma metastatic07.21.09.006; 16.13.10.0030.000139%Not Available
Pulmonary mycosis22.07.08.013; 11.03.05.0270.000533%Not Available
Recurrent cancer16.16.01.0150.000139%Not Available
Septic embolus24.01.01.032; 11.01.11.0150.000139%Not Available
Splenic haemorrhage01.09.02.015; 24.07.01.080; 12.01.02.0140.000139%Not Available
Systemic mastocytosis10.02.01.014; 01.05.01.0110.000139%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.000208%Not Available
Anaemia of malignant disease01.03.04.0030.000533%Not Available
Lumbar vertebral fracture15.08.05.007; 12.04.04.0070.000533%Not Available
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.000139%Not Available
Sinusitis aspergillus22.07.03.028; 11.03.01.0060.000799%Not Available
Hepatosplenic candidiasis11.03.03.024; 09.01.11.003; 01.09.02.0090.000533%Not Available
Pulmonary sepsis22.07.01.014; 11.01.11.0140.000764%Not Available
Febrile infection08.05.02.014; 11.01.08.0520.000278%Not Available
Tumour associated fever16.32.03.0290.000533%Not Available
Herpes oesophagitis11.05.02.025; 07.19.06.0050.000533%Not Available
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages